Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
AEMD Transcript
Aethlon Medical, Inc. (AEMD) Q4 2026 Earnings Call Transcript
Neutral6-10
Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript
Unknown2-12
The earnings call indicates mixed signals. The basic financial performance shows increased revenue but also higher operating losses, resulting in a neutral sentiment. The product development updates, particularly the progression to Cohort 2 in the oncology trial and the potential integration with the SLAMB system, are promising but face regulatory hurdles. Market strategy and expenses reflect positive cost management, though uncertainties remain. The Q&A reveals cautious optimism but lacks concrete data on treatment efficacy, leading to a neutral sentiment overall. Without market cap data, the prediction remains neutral.
Aethlon Medical, Inc. (AEMD) Q2 2026 Earnings Call Transcript
Unknown11-12
The earnings call reveals several concerns: limited cash balance raising sustainability doubts, a decision to not proceed with the India trial, and challenges in patient recruitment. Despite reduced expenses, the financial health is precarious. The Q&A section highlights uncertainties in trial outcomes and management's evasive responses, which further dampen sentiment. The combination of these factors suggests a negative outlook for the stock price.
Aethlon Medical, Inc. (AEMD) Q1 2026 Earnings Call Transcript
Unknown8-13
The earnings call highlights several risks and challenges, including regulatory delays, financial constraints, and clinical trial uncertainties. Despite positive preclinical data and cost-saving measures, the company's limited cash balance and operational risks overshadow potential benefits. The Q&A section revealed management's hesitance to provide clear guidance on trial timelines and efficacy, further dampening investor sentiment. The decision to halt the India trial due to regulatory issues adds to the negative outlook. Overall, these factors suggest a negative stock price reaction in the short term.
AEMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
